834 Retinoid X receptor agonists enhances type I systemic and intratumoral immunity, but enhanced tumor prevention, with the HER2-IGFBP2-IGF1R plasmid vaccine in two mouse mammary tumor models

• Mary L Disis,
• Sasha E Stanton,
• Shizuko Sei,
• Lauren Corulli,
• Rodmaker Erin,
• Nicholas Drovetto,
• Venkatram Atigadda,
• Clinton Grubbs

Affiliations

Mary L Disis

4University of Washington, Seattle, WA, USA

Sasha E Stanton

1Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, OR, USA

Shizuko Sei

4National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Lauren Corulli

2University of Washington, Seattle, WA, USA

Rodmaker Erin

2University of Washington, Seattle, WA, USA

Nicholas Drovetto

2University of Washington, Seattle, WA, USA

Venkatram Atigadda

3University of Alabama, Birmingham, AL, USA

Clinton Grubbs

3University of Alabama, Birmingham, AL, USA